CTOs on the Move

Santaris Pharma A/S USA

www.santaris.com

 
Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.santaris.com
  • 12626 High Bluff Dr Ste 440
    San Diego, CA USA 92130
  • Phone: 858.764.7064

Executives

Name Title Contact Details

Similar Companies

InnovaSystems

InnovaSystems is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADV-Care Pharmacy Inc

ADV-Care Pharmacy Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services with licenses in 18 US jurisdictions and the EU. Columbia Care is one of the original providers of medical cannabis in the United States, and continues to deliver an industry-leading, patient-centered medicinal cannabis operation that has quickly expanded into the adult use market as a premier operator. The company currently offers products spanning flower, edibles, oils, and tablets, and manufactures popular brands including Amber and Platinum Label CBD. With more than four million sales transactions since its inception in 2012, Columbia Care is known for setting the standard for compassion, professionalism, quality, care, and innovation in the rapidly expanding cannabis industry. Must be 21+ to follow.

Pafford Medical Services

With one call, Pafford Medical Services facilitates every component of patient transport on both sides of the horizon.

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.